Three scientific posters highlighting novel anti-virulence pharmacologic properties of oral ibezapolstat for C. difficile Infection; effects on toxin production, biofilm and the gut microbiomeA.
Although antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence.
STATEN ISLAND, N.Y., Aug. 14, 2023 /PRNewswire/ Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial. -Today at 07:02 am- MarketScreener
Can elderly patients safely stop MS treatment? Study to find out | 'Urgent' study by new US university center funded by $1.6M grant multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.